Hanish Patel, OD

In our practice at the Eye Institute and Laser Center in Manhattan, over the past several years virtually all of our patients have had an Optomap Retinal Exam (Optos, Marlborough, Mass.), and virtually all detected lesions have been subjected to critical cross-sectional analysis with the OCT Stratus (Carl Zeiss Meditec, Dublin, Calif.). Within the last year, at least six next-generation OCTs have become commercially available. These new OCTs, known as either spectral domain (SD) or frequency or Fourier domain, represent at least an evolution – if not a revolution – with regard to in vivo retinal dissection.